Revance to Participate in Upcoming June 2024 Investor Conferences

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced that the company will be participating in the following investor conferences.

William Blair 44th Annual Growth Stock Conference
Chief Financial Officer Tobin Schilke is scheduled to present on Tuesday, June 4, 2024, at 11:20 am CT, in Chicago, Illinois.

Goldman Sachs 45th Annual Global Healthcare Conference
President and Chief Executive Officer Mark J. Foley is scheduled to present on Tuesday, June 11, 2024, at 8:00 am ET, in Miami, Florida.

Interested parties can access the live audio webcasts for the conferences from the Investor Relations section of the company’s website at www.revance.com. The webcast replays will be available after the conclusion of the live presentations for approximately 90 days.

About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China.

Revance’s global headquarters and experience center is located in Nashville, Tennessee. Learn more at Revance.com, RevanceAesthetics.com, DAXXIFY.com, HCP.DAXXIFYCervicalDystonia.com, or connect with us on LinkedIn.

“Revance”, the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240528756057/en/